Format

Send to

Choose Destination
Anticancer Res. 2016 Dec;36(12):6347-6356.

Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer.

Author information

1
Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece pectasid@otenet.gr hecogoff@otenet.gr.
2
Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
3
Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
4
Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece.
5
Health Data Specialists Ltd., Athens, Greece.
6
First Department of Surgery, Konstantopoulio Agia Olga General Hospital, Athens, Greece.
7
Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
8
Department of Pathology, Konstantopoulio Agia Olga General Hospital, Athens, Greece.
9
Translational Research Section, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
10
Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.

Abstract

AIM:

The aim of this study was to evaluate the mRNA expression pattern of growth- and survival-related genes and assess their prognostic significance in patients with advanced pancreatic cancer.

PATIENTS AND METHODS:

In total, 98 patients were included in this retrospective translational research study and were evaluated for Kirsten rat sarcoma viral oncogene homolog (KRAS) mutational status, and v-akt murine thymoma viral oncogene homolog 1 (AKT1), AKT serine/threonine kinase 2 (AKT2), AKT serine/threonine kinase 3 (AKT3), cyclin D1 (CCND1), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 (MAPK1), hepatocellular growth factor receptor (MET), avian myelomatosis viral oncogene homolog (MYC), nuclear factor kappa B subunit 1 (NFKb1), phosphatase and tensin homolog (PTEN) and mechanistic target of rapamycin (FRAP1) genes mRNA expression. Among these patients, 73 received first-line gemcitabine combined with erlotinib (N=57) or gefitinib (N=16).

RESULTS:

KRAS mutation did not correlate with mRNA gene expression. Unsupervised hierarchical clustering according to mRNA gene expression successfully distinguished four prognostically distinct groups of tumors. Overexpression of all genes was associated with best prognosis, while suppression or heterogeneous expression patterns of the examined genes were associated with expression patterns of growth- and survival-related genes, classifying pancreatic tumors into distinct groups with possibly different outcomes.

KEYWORDS:

EGFR; KRAS; Pancreatic cancer; hierarchical clustering analysis; mRNA expression; prognosis

PMID:
27919956
DOI:
10.21873/anticanres.11232
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center